SCHEMBL30749035

SCHEMBL30749035

Clc1nccc(Nc2ccc(N3CCOCC3)nc2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 1/20 0.52
▸ MAPT P10636 3/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ LMNA P02545 2/20 0.50
▸ HTT P42858 1/20 0.50
▸ PLK4 O00444 1/20 0.49
▸ RAB9A P51151 3/20 0.48
▸ IGF1R P08069 1/20 0.47
▸ AURKA O14965 1/20 0.47
▸ AURKB Q96GD4 1/20 0.47
▸ CNR2 P34972 4/20 0.45
▸ DGAT1 O75907 2/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ SMG1 Q96Q15 1/20 0.44
▸ NPC1 O15118 2/20 0.44
▸ FLT3 P36888 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748815 0.84 SORD (0.47) MAPTSMN1; SMN2LMNAHTTPLK4
SCHEMBL6982507 0.84 PLK4 (0.67) MAPK14MAPTSMN1; SMN2PLK4IGF1R
SCHEMBL30748724 0.82 PLK4 (0.46) MAPTSMN1; SMN2LMNAHTTPLK4
SCHEMBL17224821 0.82 MAPT (0.51) MAPTSMN1; SMN2LMNAHTTPLK4
SCHEMBL31691298 0.81 MAPT (0.49) MAPTSMN1; SMN2LMNAHTTPLK4
SCHEMBL31691197 0.78 MAPT (0.49) MAPTSMN1; SMN2LMNAHTTRAB9A
SCHEMBL30748886 0.78 MAPT (0.48) MAPTSMN1; SMN2LMNAHTTRAB9A
SCHEMBL28221625 0.78 PLK4 (0.56) PLK4IGF1RAURKAAURKBSMG1
SCHEMBL23887632 0.77 PLK4 (0.74) PLK4IGF1RAURKAAURKB
SCHEMBL4504400 0.76 RAB9A (0.52) MAPTSMN1; SMN2LMNAHTTPLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 — — US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 — — EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT MAPK14 3617/4885MAPT 3029/4885SMN1; SMN2 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback